CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes

  • sponsor
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Updated on 25 March 2021


CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes


The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial.

All subjects will receive close monitoring for development of AGT or T1DM. Subjects will receive Abatacept or placebo and close monitoring for development of AGT or T1DM. To assess the safety, efficacy, and mode of action of Abatacept to prevent AGT and T1DM.

The primary objective is to determine whether intervention with Abatacept will prevent or delay the development of AGT in at-risk autoantibody positive non-diabetic relatives of patients with T1DM.

Secondary outcomes include: the effect of Abatacept on the incidence of T1DM; analyses of C-peptide and other measures from the OGTT; safety and tolerability; and mechanistic outcomes.

Clinical Study IdentifierTX139938
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Last Modified on25 March 2021


Yes No Not Sure

Inclusion Criteria

Participant in TrialNet Natural History/Pathway to Prevention Study and thus, a relative of a proband with T1DM
Between the ages of 1-45 years at the time of enrollment in TN01 and age ≥ 6 at time of randomization in this trial
Willing to provide Informed Consent or have a parent or legal guardian provide informed consent if the subject is <18 years of age
Normal glucose tolerance by OGTT confirmed within 7 weeks (no more than 52 days) of baseline (visit 0). If previous abnormal glucose tolerance, has had two consecutive OGTTs with normal glucose tolerance
Fasting plasma glucose < 110 mg/dL (6.1 mmol/L), and
hour plasma glucose <140 mg/dL (7.8 mmol/L), and
60, or 90 minute value on OGTT< 200mg/dL (11.1 mmol/L)
At least two diabetes-related autoantibodies confirmed to be present on two occasions, not including mIAA. Confirmation of 2 positive autoantibodies must occur within the six months prior to randomization, but the confirmation does not have to involve the same 2 autoantibodies
Weight ≥ 20 kg at Baseline Visit
If a female participant with reproductive potential, willing to avoid pregnancy and undergo pregnancy testing prior to each infusion
At least three months from date of last live immunization
Willing to forgo live vaccines while receiving treatment on study and for three months following last study drug administration

Exclusion Criteria

Abnormal Glucose Tolerance or Diabetes
Fasting plasma glucose ≥ 110 mg/dL (6.1 mmol/L), or
hour plasma glucose ≥ 140 mg/dL (7.8 mmol/L), or
60, 90 minute plasma glucose during OGTT ≥ 200 mg/dL (11.1 mmol/L)
Insulin autoantibodies (mIAA)
Are immunodeficient or have clinically significant chronic lymphopenia
Have an active infection at time of randomization
Have a positive PPD test result or history of previously treated TB, or positive interferon-gamma release assay (IGRA) test
Be currently pregnant or lactating, or anticipate getting pregnant within 3 months of the last study drug administration
Use of medications known to influence glucose tolerance
Require use of other immunosuppressive agents
Have serologic evidence of current or past HIV, Hepatitis B (positive for Hepatitis B core antibody or surface antigen), or Hepatitis C infection
Have serological evidence of current CMV infection
Have evidence of active EBV infection
Have any complicating medical issues or abnormal clinical laboratory results that interfere with study conduct or cause increased risk. These include pre-existing cardiac disease, COPD, neurological, or blood count abnormalities (such as lymphopenia, leukopenia, or thrombocytopenia)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note